Rabeprazole. A review of its use in acid-related gastrointestinal disorders

Drugs

Volumn 58, Issue 4, 1999, Pages 725-742

  Langtry, Heather D ^a   Markham, Anthony ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; KETOCONAZOLE; OMEPRAZOLE; PROTON PUMP; RABEPRAZOLE; RANITIDINE;

ACID SECRETION; ANTIBACTERIAL ACTIVITY; BACTERIAL INFECTION; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DUODENUM ULCER; FLU LIKE SYNDROME; GASTROESOPHAGEAL REFLUX; HEADACHE; HELICOBACTER PYLORI; HUMAN; INFECTION; MAJOR CLINICAL STUDY; META ANALYSIS; ORAL DRUG ADMINISTRATION; RASH; REVIEW; STOMACH ULCER; ULCER HEALING; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS; ENZYME INHIBITORS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OMEPRAZOLE; PEPTIC ULCER;

BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

EID: 0032750985     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958040-00014     Document Type: Review

References (62)

1. 1. Wilde MI, McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994 Jul; 48: 91-132
2. 2. Langtry HD, Wilde MI. Omeprazole: a review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs 1998 Sep; 56: 447-86
3. 3. Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997 Sep; 54: 473-500
4. 4. Fitton A, Wiseman L. Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996 Mar; 51: 460-82
5. 5. Beardi RR, Welage LS. Proton-pump inhibitors in acid-related diseases. Am J Health System Pharm 1998 Nov 1; 55: 2289-98
6. 6. Humphries TJ, Barth J. Review article: rabeprazole's profile in patients with gastrointestinal diseases. Aliment Pharmacol Ther 1999; 13 Suppl. 5. In press
7. +-ATPase inhibitors, omeprazole and E3810. J Biol Chem 1993 Oct 15; 268: 21553-9
8. 8. Morii M, Takeguchi N. The binding site of E3810 to gastric proton pump [abstract]. 10th World Congress of Gastroenterology; 1994 Oct 2-9: Los Angeles (CA), 1995P
9. 9. Morii M, Takeguchi N. The conformational state of proton pump is differently affected by omeprazole, lansoprazole and E3810 [abstract]. 10th World Congress of Gastroenterology; 1994 Oct 2-9: Los Angeles (CA), 1994P
10. +-ATPase is correlated with the rate of acid-activation of the inhibitor. Biochem Pharmacol 1990 Feb 15; 39: 661-7
11. 11. Shibata H, Murakmai M, Fujimoto M, et al. Histamine-stimulated gastric acid secretion is inhibited in gastric fistula dogs treated with E3810 (2-[4-(3-methoxypropoxy)-3-methylpyridin-2-ylmethyl sulfinyl]-1H-benzim idazole, sodium) [abstract]. FASEB J 1990 Feb 26; 4: A473
12. 12. Takeguchi N, Tomiyama Y, Morii M. The intracellular cycling of gastric proton pump is differently affected by E3810 and lansoprazole in rats [abstract]. 10th World Congress of Gastroenterology; 1994 Oct 2-9; Los Angeles (CA), 1996P
13. 13. Inoue M, Shirakawa T, Murakami Y, et al. Effect of a new proton pump inhibitor E3810 on intragastric pH in the patients with peptic ulcer [abstract]. Gastroenterology 1991 May; 100 Suppl.: 89
14. 14. Williams MP, Sercombe J, Hamilton MI, et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998 Nov; 12: 1079-89
15. 15. Kovacs TOG, Sytnik B, Humphries TJ, et al. A low dose of a new proton pump inhibitor LY-307640 (E3810) effectively inhibits acid secretion in humans [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A161
16. 16. Lew EA, Barbuti RC, Kovacs TOG, et al. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810). Aliment Pharmacol Ther 1998 Jul; 12: 667-72
17. 17. Robinson M, Maton PN, Rodriguez S. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastrooesophageal reflux disease. Aliment Pharmacol Ther 1997 Oct; 11: 973-80
18. 18. Pounder RE, Blanshard C, Millson C et al. Effects of rabeprazole on 24-hour intragastric acidity and plasma gastrin in healthy subjects [abstract]. 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 Mar 5-8: San Diego (CA), 169
19. 19. Bell NE, Humphries TJ. Comparison of fasting serum gastrin levels in 634 patients treated with either rabeprazole 20mg or omeprazole 20mg once daily in 3 double-blind therapeutic trials [abstract]. Gastroenterology 1997 Apr; 112 (4) Suppl.: A70
20. 20. Humphries T, Dekkers C, Beker J, et al. Magnitude of changes in fasting serum gastrin in 211 patients taking rabeprazole 10 mg or 20 mg or omeprazole 20 mg for one year [abstract]. Am J Gastroenterol 1998 Sep; 93: 1637
21. 21. Fujiyama K, Fujioka T, Kodama R, et al. Effect of E3810, a novel proton pump inhibitor, against Helicobacter pylori [abstract]. Am J Gastroenterol 1994 Aug; A89: 1371
22. 22. Satoh M, Tonomura H, Murakami M, et al. In vitro activity of E3810/LY307640, a novel proton pump inhibitor, against Helicobacter pylori [abstract]. 10th World Congress of Gastroenterology; 1994 Oct 2-9: Los Angeles (CA), 196P
23. 23. Moore R, Bryan LE, Satoh M, et al. Anti-Helicobacter pylori activity synergy between amoxicillin and the thioether derivative of the proton pump inhibitor E3810/LY307640 [abstract]. 10th World Congress of Gastroenterology; 1994 Oct 2-9: Los Angeles (CA), 197P
24. 24. Tsuchiya M, Imamura L, Park JB, et al. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 1995 Aug; 18: 1053-6
25. 25. Park JB, Imamura L, Kobashi K. Kinetic studies of Helicobacter pylori urease inhibition by a novel proton pump inhibitor, rabeprazole. Biol Pharm Bull 1996 Feb; 19: 182-7
26. 26. Pospai D, Cadiot G, Vissuzaine C, et al. Fundic mucosa of GER patients continuously treated with ranitidine: comparison with omeprazole-treated patients and controls [abstract]. Gastroenterology 1995; 108 (4): A194
27. 27. Anonymous. Proton pump inhibitor relabeling for cancer risk not warranted. FDC Rep Pink Sheet 1996 Nov 11; 58: 1-2
28. 28. Humphries TJ. Rabeprazole sodium: is it possible to improve the benefit risk equation for proton pump inhibitors (PPI)? Gut 1996 Nov; 39: A777
29. 29. Humphries T, Rindi G, Fiocca R. Argyrophil ECL cell histology in the gastric corpus and antrum in 243 patients taking rabeprazole 10 mg or 20 mg or omeprazole 20 mg for one year [abstract]. Am J Gastroenterol 1998 Sep; 93: 1637
30. 30. Takiuchi H, Asada S, Umegaki E, et al. Effects of proton pump inhibitors, omeprazole, lansoprazole and E-3810, on the gastrin mucin [abstract]. 10th World Congress of Gastroenterology; 1994 Oct 2-9: Los Angeles (CA), 1404P
31. 31. Goto H, Tsukamoto Y, Ohara A, et al. Effects of decreased leukotrienes by proton pump inhibitors on water immersion stress-induced gastric ulcers in rats [abstract]. Gastroenterology 1992 Apr; 102 (Pt 2): A75
32. 32. Dammann HG, Burkhardt F, Bell NE, et al. Rabeprazole does not affect endocrine function in healthy subjects [abstract no. 646]. Am J Gastroenterol 1996 Sep; 91: 1909
33. 33. Takakuwa S, Chiku S, Nakata H, et al. Enantioselective pharmacokinetics of E3810, a new anti-ulcer agent, in dogs and rats [abstract]. 7th North American Meeting of the International Society for the Study of Xenobiotics; 1996 Oct 19-24: San Diego, (CA); 10: 346
34. 34. Yasuda S, Ohnishi A, Ogawa T, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther 1994 Sep; 32: 466-73
35. + ATPase inhibitor (E3810) and its four metabolites in human plasma hy high-performance liquid chromatography. J Chromatogr B Biomed Appl 1994 Oct 3; 660: 211-20
36. 36. VandenBranden M, Ring BJ, Binkley SN, et al. Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 1996 Feb; 6: 81-91
37. 37. Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status. Clin Pharmacol Ther 1995 Aug; 58: 143-54
38. 38. Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation. Clin Pharmacol Ther 1995 Aug; 58: 155-64
39. 39. Fujisaki H, Oketani K, Nagakawa J-i, et al. Effects of rabeprazole, a gastric proton pump inhibitor, on biliary and hepatic lysosomal enzymes in rats. Jpn J Pharmacol 1998 Mar; 76: 279-88
40. 40. Spera A, Merritt J, Keane W, et al. Rabeprazole 20mg does not appear to require dosage adjustment in elderly patients or those with renal or hepatic disease [abstract no. ExhB1069]. Digestion 1998; 59 Suppl. 3: 76
41. 41. Hoyumpa AM, Trevino-Alanis H, Grimes I, et al. Rabeprazole: pharmacokinetics in patients with stable compensated cirrhosis. Clin Ther 1999 Apr; 21 (4): 691-701
42. 42. Laurent AL, Merritt GJ, Setoyama T, et al. Rabeprazole: pharmacokinetics and safety in the elderly. Clin Geriatr 1999 May; 7 (6): 27-33
43. 43. Humphries TJ, Keane WF, St. Peter JV, et al. Rabeprazole, safety, tolerance, and pharmacokinetics in patients with renal dysfunction [abstract]. Am J Gastroenterol 1998; 93 (9): 1638
44. 44. Yasuda S, Higashi S, Murakami M, et al. Antacids have no influence on the pharmacokinetics of rabeprazole, a new proton pump inhibitor, in healthy volunteers. Int J Clin Pharmacol Ther 1998; 37 (5): 249-53
45. 45. Humphries TJ, Nardi RV, Lazar JD, et al. Drug-drug interaction evaluation of rabeprazole sodium: a clean/expected slate? [abstract]. Gut 1996; 39 Suppl. 3: A47
46. 46. Cloud ML, Enas N, Humphries TJ, et al. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998 May; 43: 993-1000
47. 47. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20mg versus omeprazole 20mg in the treatment of active duodenal ulcer: a European multicentre study. Aliment Pharmacol Ther 1999; 13: 179-86
48. 48. Humphries TJ. Spera A, Breiter J, et al. Rabeprazole sodium once daily is superior to ranitidine 150mg BID in the healing of active duodenal ulcer [abstract]. Gastroenterology 1997 Apr; 112 (4) Suppl.: A154
49. 49. Dekkers CP, Beker JA, Thjodleifsson B, et al. Comparison of rabeprazole 20mg vs. omeprazole 20mg in the treatment of active gastric ulcer - a European multicentre study. The European Rabeprazole Study Group. Aliment Pharmacol Ther 1998 Aug; 12: 789-95
50. 50. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Double-blind, placebo-controlled comparison of rabeprazole 20mg vs. omeprazole 20mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999 Jan; 13: 49-57
51. 51. Delchier JC, Cohen G, Humphries TJ, et al. Rabeprazole is comparable in efficacy to omeprazole in erosive GORD and provides more rapid heartburn relief [abstract no. TH446]. Gut 1999; 44 Suppl. I: A112
52. 52. Humphries TJ, Spera A, Breiter J, et al. Rabeprazole sodium (E3810) once daily is superior to ranitidine 150 mg QID in the healing of erosive or ulcerative gastroesophageal reflux disease [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A139
53. 53. Birbara C, Breiter J, Collins D, et al. Rabeprazole: preventing endoscopic and symptomatic relapse in erosive or ulcerative GERD [abstract]. Am J Gastroenterol 1998 Sep; 93: 1630
54. 54. Humphries TJ, Dekkers CPM, Beker JA, et al. Rabeprazole vs omeprazole for maintenance therapy of healed erosive GERD: results of a 1-year multicenter trial [abstract]. Am J Gastroenterol 1998 Sep; 93: 1616
55. 55. Humphries TJ, Bassion S, Spanyers SA. Pilot studies on the effects of rabeprazole sodium (E3810), amoxicillin, and placebo on the eradication of H. pylori [abstract]. Am J Gastroenterol 1996 Sep; 91: 1914
56. 56. Stack WA, Knifton A, Thirlwell D, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am J Gastroenterol 1998 Oct; 93: 1909-13
57. 57. Miwa H, Ohkura R, Murai T, et al. Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection - comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 1999; 13: 741-6
58. 58. Mignon M, Merrouchem M, Gardner J, et al. Rabeprazole therapy effective in Zollinger-Ellison syndrome and idiopathic gastric acid hypersecretion [abstract no. TH500]. Gut 1999 Apr; 44 Suppl. 1: A125
59. 59. Johnson D, Riff R, Perdomo C, et al. Rabeprazole: safety profile of a new proton pump inhibitor [abstract no. G0875]. Gastroenterology 1999 Apr; 116 (4)
60. 60. Eisai Ltd. Rabeprazole prescribing information. London. England, 1998
61. 61. Ikeda S, Ikegami N. Cost-effectiveness of proton pump inhibitors in gastric ulcer [abstract]. Pharmacoepidemiol Drug Saf 1998 Aug; 7 Suppl. 2: S92
62. 62. Ofman JJ, Yamashita BD, Siddique RS, et al. Cost-effectiveness of rabeprazole versus ranitidine in reflux esophagitis [abstract]. Value in Health 1999 May/Jun; 2 (3); 154